Share This Page
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Clindamycin Phosphate In 0.9% Sodium Chloride patents expire, and what generic alternatives are available?
Clindamycin Phosphate In 0.9% Sodium Chloride is a drug marketed by Baxter Hlthcare Corp and is included in one NDA.
The generic ingredient in CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Clindamycin Phosphate In 0.9% Sodium Chloride
A generic version of CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE was approved as clindamycin phosphate by HIKMA on April 25th, 1988.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE?
- What are the global sales for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE?
- What is Average Wholesale Price for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE?
Summary for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
US Patents and Regulatory Information for CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE | clindamycin phosphate | SOLUTION;INTRAVENOUS | 208083-001 | Apr 20, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Baxter Hlthcare Corp | CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE | clindamycin phosphate | SOLUTION;INTRAVENOUS | 208083-002 | Apr 20, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Baxter Hlthcare Corp | CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE | clindamycin phosphate | SOLUTION;INTRAVENOUS | 208083-003 | Apr 20, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Investment Scenario and Patent/Regulatory Fundamentals for Clindamycin Phosphate in 0.9% Sodium Chloride (IV)
Clindamycin phosphate in 0.9% sodium chloride is an IV antibiotic combination presentation (active ingredient: clindamycin phosphate) with mature commercialization and a patent landscape dominated by legacy drug substance and formulation coverage that typically cleared long ago. The investable profile is therefore driven less by near-term exclusivity scarcity and more by manufacturing economics, FDA listing/entry risk, complex generic/regional procurement dynamics, and supply reliability for hospitals and specialty distributors.
What is clindamycin phosphate in 0.9% sodium chloride and how is it used clinically?
Featured snippet answer: It is an IV formulation of clindamycin phosphate diluted in 0.9% sodium chloride used for serious bacterial infections where IV clindamycin is indicated.
Clindamycin (lincosamide) is used for infections caused by susceptible anaerobic bacteria and susceptible Gram-positive organisms. The IV presentation is commonly used in inpatient settings, often when oral therapy is not feasible.
Typical therapeutic targets and infection types
Clindamycin is generally positioned for:
- Skin and soft tissue infections
- Intra-abdominal infections (in combination regimens)
- Dental and odontogenic infections
- Bone and joint infections (in combination, depending on susceptibility)
- Gynecologic and pelvic infections (clinician-dependent regimens)
How the IV dilution affects product classification
The presence of 0.9% sodium chloride indicates an IV dilution vehicle commonly used for IV infusion delivery. In practice, investment risks and margins are tied to:
- sterile manufacturing yield and sterility assurance
- container closure and infusion compatibility
- stability specs and shelf life
- procurement contracts that penalize shortages
What is the FDA regulatory status of clindamycin phosphate in 0.9% sodium chloride and how many approved products exist?
Featured snippet answer: The product is an established, FDA-approved generic-market antibiotic presentation with multiple listed manufacturers under Abbreviated New Drug Application (ANDA) listings or legacy approvals, depending on the specific label strength and package.
For an investment-grade view, the key question is the Orange Book population and whether any supplier has a period of new exclusivity. For mature antibiotics, the Orange Book is typically populated by many ANDA holders, with patent cliffs driven by old composition-of-matter or formulation patents already expired.
What to check in Orange Book listings (investment lens)
- Number of NDA/ANDA entries for the exact strength and dosage form (clindamycin phosphate in 0.9% sodium chloride for IV)
- Whether any listed patents are currently “active” (unexpired) and tied to this specific presentation
- Whether the listed patents are new drug patents (rare in this segment) versus old patents that have already expired
Commercial implication: If there are multiple ANDA holders with no active Orange Book patents, the equilibrium pricing is supply-and-contract-driven rather than exclusivity-driven.
How does clindamycin phosphate in 0.9% sodium chloride compare with other clindamycin IV products (stability, supply, and interchangeability)?
Featured snippet answer: From an investment perspective, this presentation competes with other IV clindamycin forms through therapeutic interchangeability, procurement consolidation, and supply reliability rather than patent-protected differentiation.
Interchangeability drivers
- Therapeutic substitution by clinicians
- Formulary decisions (hospital preference and drug utilization management)
- Infusion workflow compatibility (bag/pump compatibility, labeling, infusion duration)
- Supply continuity during manufacturing outages
Interchangeability risk to revenue forecasts
If competitors experience stockouts, the market temporarily shifts demand to available SKUs. Conversely, when all suppliers normalize supply, pricing pressure returns quickly.
What patents protect clindamycin phosphate in 0.9% sodium chloride, and when did they expire?
Featured snippet answer: Patent protection for clindamycin phosphate IV formulations has largely cleared. Any remaining active patents, if present, are typically narrow formulation, packaging, or method-of-use patents that do not materially constrain generic competition for the core IV product.
Patent estate characteristics in mature antibiotics
In broad practice, drug substance patents for antibiotics like clindamycin are typically long expired. Residual protection, when it exists, tends to be:
- process-related patents (manufacturing methods)
- formulation stability/compatibility patents
- packaging/container closure patents
- method-of-use patents (less common for widely used antibiotics)
How this shapes investment strategy
- Expect limited “duration of competitive moat”
- Focus on operational moat: quality, supply assurance, contract execution, and unit-cost advantages
- Treat “new exclusivity events” as low probability for such mature products unless specific RMF or reformulation exclusivity is present in the Orange Book
When does clindamycin phosphate in 0.9% sodium chloride lose exclusivity, and what triggers generic entry risk?
Featured snippet answer: Exclusivity loss generally occurred years ago; generic entry risk is therefore driven by supply capacity, ANDA ownership concentration, and manufacturing outages rather than legal cliff timing.
Generic entry triggers in the IV antibiotic segment
- ANDA approvals for identical strengths/dosage forms
- contract manufacturer scaling and sterile facility expansions
- transfer of manufacturing site (risk: regulatory CMC changes)
- shortages triggering temporary demand shifts
Investment timing implication
The investment window is less about waiting for a patent expiry and more about identifying:
- whether any supplier is capacity-constrained
- whether regulatory or CMC events are likely to reduce availability
- whether a manufacturer’s cost structure allows sustained profitability in a low-margin segment
What is the Orange Book status of clindamycin phosphate in 0.9% sodium chloride?
Featured snippet answer: Orange Book protection is typically limited or expired for this mature IV antibiotic presentation; the product generally operates as a multi-source generic.
What that means for investors
- Pricing power is contract-driven and sensitive to supply tightness
- Litigation or new patent listings rarely alter the fundamental demand-supply equilibrium
- Returns depend on execution, not on patent-driven exclusivity
How strong is the patent estate for clindamycin phosphate IV presentations?
Featured snippet answer: Patent strength is generally low for this category as a competitive moat. Where patents remain, they are usually narrow and do not block multi-source generic supply.
Patent strength scoring framework (how funds underwrite this)
For mature antibiotics, investors typically grade patent estate on:
- number of remaining listed patents in Orange Book
- breadth of claims to the exact formulation/diluent/presentation
- likelihood that a generic could design around without bioequivalence issues (typically manageable)
Practical outcome
- Patent-based blocking is uncommon
- Competitive advantage comes from supply, COGS, and regulatory risk management
What patent litigation affects clindamycin phosphate in 0.9% sodium chloride?
Featured snippet answer: Litigation risk exists in any generic-heavy antibiotic space but is usually not a dominant driver of market structure for established clindamycin IV presentations after major patent estates expire.
Where litigation does matter
- If a specific supplier recently launched and is still defending a narrow patent
- If a challenger targets a formulation/packaging patent unique to that supplier
- If a settlement delays entry for a short time
Investment lens
Given typical maturity, litigation becomes relevant when:
- one supplier exits due to settlement or manufacturing constraints
- courts affect a narrow design-around strategy that impacts availability
Are there biosimilar or biologics risks for clindamycin phosphate in 0.9% sodium chloride?
Featured snippet answer: No. Clindamycin is a small-molecule antibiotic and does not have a biologics/biosimilars framework.
Investment focus remains on ANDAs, CMC comparability, sterile manufacturing, and supply chain reliability.
What formulations are protected in this product class (and what design-arounds are typical)?
Featured snippet answer: The most plausible formulation/IP residuals are compatibility, stability, and container closure method patents. Generic design-around typically targets manufacturing process and packaging while retaining labeled equivalence.
Typical formulation protection angles
- stability at relevant storage conditions
- infusion compatibility with clinical administration sets
- pH and ionic strength tolerances within labeling limits
- container closure compatibility to prevent leachables or adsorption
Design-around impact on timeline and cost
- If process patents exist, they may raise CMC burden
- If packaging patents exist, container sourcing may become a differentiator
- These do not usually stop entry long-term in multi-source antibiotic categories
How many patents cover clindamycin phosphate in 0.9% sodium chloride across major jurisdictions?
Featured snippet answer: In practice, coverage is distributed among legacy, process, and formulation filings; by the time the IV presentation is multi-source, many relevant filings are expired or non-blocking.
Jurisdictional relevance
For investors, the key is not “how many filings exist,” but:
- which patents are listed in the US Orange Book for the exact dosage form and strength
- whether any are unexpired and enforceable against ANDA entry
Non-US filings rarely matter unless they map to US listed patents or are tied to manufacturing exclusivity/settlements.
Which companies typically compete in clindamycin phosphate IV markets, and what are the implications?
Featured snippet answer: Competition is generally multi-source with multiple ANDA manufacturers; pricing and availability are driven by procurement contracts and sterile manufacturing capacity.
Competitive dynamics that matter financially
- Supplier concentration in sterile facilities
- Quality incidents and recalls that force temporary withdrawal
- Contract coverage with group purchasing organizations (GPOs)
- Ability to maintain shelf life at scale
Implication for investors
- Underwrite downside risk from supply normalization
- Underwrite upside from constrained competitors or disruptions that keep prices elevated
What generic entry risks exist for this clindamycin IV presentation?
Featured snippet answer: Entry risk is low in the sense that the market is already populated; the bigger risk is that additional supply depresses pricing or that supply disruptions create volatility in revenue.
Entry mechanics in this segment
- ANDA approvals typically occur with limited differentiation
- Clinical interchangeability supports rapid switch
- Procurement contracts can lag demand shocks
What manufacturing and IP barriers can slow supply for clindamycin phosphate in 0.9% sodium chloride?
Featured snippet answer: Supply barriers tend to be CMC and sterile production constraints, not patent barriers.
Key production bottlenecks
- sterile filtration/aseptic fill capacity
- media fill success rates
- batch yield and sterility assurance cost
- container closure sourcing and QC release time
- stability testing burden at commercial scale
IP-adjacent constraints
If any process patents remain in specific manufacturing routes, design-around may require:
- new equipment train validation
- requalification and comparability updates
- additional stability studies
How does clindamycin phosphate in 0.9% sodium chloride impact revenue exposure for buyers and investors?
Featured snippet answer: Revenue is typically modest margin with high sensitivity to contract pricing and supply reliability; demand is relatively inelastic in hospital settings but inventory volatility can occur during shortages.
What drives revenue in practice
- inpatient volume and prescribing protocols
- formulary placement and GPO contract pricing
- competition intensity and number of supply sources
- shortage events and allocation practices
What drives profitability
- COGS: API cost, sterile processing overhead, and yield
- wastage: out-of-spec release risk and retesting
- working capital and inventory turns given shelf life
- logistics and distributor terms
What investment scenario best fits this drug: hold, enter, or exit?
Featured snippet answer: For new investment, the strategy is typically “enter only if you have a cost and supply advantage,” because IP-driven monopolistic pricing is unlikely. For incumbents, the strategy is “defend supply continuity and keep unit costs below contract benchmarks.”
Hold scenario (existing supplier)
- Objective: maintain uninterrupted supply, protect quality, and sustain contract renewals
- Main risk: price erosion as competitors’ capacity returns
Enter scenario (new supplier)
- Objective: win contract tenders by offering reliability and competitive unit pricing
- Main risk: market normalization compresses margins after ramp-up
Exit scenario
- Objective: avoid low-margin exposure if sterile capacity is better used elsewhere
- Main risk: exit timing may be punished by short-term shortages that improve prices
Key Takeaways
- Clindamycin phosphate in 0.9% sodium chloride is a mature IV antibiotic with a multi-source generic market profile.
- Patent exclusivity is typically not a primary driver of competitive advantage; supply, sterile manufacturing economics, and contract execution dominate.
- Orange Book-driven moat is generally limited for this presentation; revenue and margins are contract and availability sensitive.
- Investment upside is most likely tied to capacity constraints or disruptions among suppliers, not to new legal barriers.
- Underwrite downside from supply normalization that quickly re-prices the class.
FAQs
What is the main competitive risk for clindamycin phosphate IV products?
Pricing compression as multi-source supply normalizes, driven by contract re-tendering and additional ANDA capacity.
How do shortages affect hospital purchasing behavior for IV clindamycin?
Hospitals shift to available SKUs, but procurement contracts and formulary rules can delay reallocation, creating short-term volatility.
Does this product face biosimilar competition risk?
No. Clindamycin is a small-molecule antibiotic, not a biologic.
What CMC factors most influence profitability in IV clindamycin formulations?
Aseptic fill yield, sterility assurance cost, stability/shelf-life compliance, and container closure QC release performance.
Is patent litigation a meaningful valuation driver here?
Usually not for mature clindamycin IV presentations. Valuation is more sensitive to supply continuity and unit economics than to pending exclusivity.
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. Drug Shortages. https://www.accessdata.fda.gov/scripts/_(drug_shortages)/_(default)/_(index)_.cfm
More… ↓
